RESEARCH & TREATMENT

Three-quarters of CAC2 member organizations fund essential research projects related to childhood and AYA cancer.  The coverage is deep and broad:  across the spectrum of development, from basic research through to clinical trials; across a wide range of topics, including data sharing, crucial medicines, psycho-social standards, and survivorship; and across the country and around the world.

Research funded by our members is crucial to discovering more effective treatments that minimize side effects and increase quality of life during and after treatment.  Most importantly, that research investment represents a shared aim to find cures for all types of childhood cancer.  CAC2 celebrates each and every member’s efforts to help close the large and persistent gap between funding needs to achieve this goal andavailable resources.

CAC2 doesn’t just applaud our member’s individual efforts but strives to act as a catalyst for research members to work collaboratively to effect positive change in the childhood cancer research community.  The Research and Treatment Interest Group has a four-pronged strategy for achieving this goal.

Research and Treatment Interest Group Strategy

Webinars, Conferences, and News
Information Repositories
Co-Funding Opportunities
Ethics and Best Practices

The Research and Treatment interest Group strives to establish CAC2 as a credible resource for moving the field of pediatric cancer forward through thoughtful, progressive studies and projects.

ALL member organizations with a research interest or focus are encouraged to participate in the work of the CAC2 Research and Treatment Interest Group. Volunteers are welcome to join a committee on a rolling basis. Please contact us at  for more information.

“Talent wins games, but teamwork and intelligence win championships.” – Michael Jordan

Ethics Think Tank
Foundation Match
ICRP Database
CAC2 Research Conference Proceedings
Research News

Latest CAC2 and Community News

CAC2 Childhood Cancer Community News Digest (March 11-17)

Assorted News from the Last Week: Feature story about CAC2 Member Beat Childhood Cancer and new FDA approved therapeutic DFMO:  Families of paediatric cancer patients have helped move a pioneering treatment for neuroblastoma from the lab to the clinic. Could ...

CAC2 Childhood Cancer Community News Digest (March 4-10)

Assorted News from the Last Week: Cancer Grand Challenges has selected five new global research teams that will address the following challenges in cancer.  This year two teams working to develop drugs for solid tumors in children were selected.  The ...

CAC2 Childhood Cancer Community News Digest (February 26-March 3)

Assorted News from the Last Week: Access to innovative therapies in pediatric oncology: Report of the nationwide experience in Canada. President’s Cancer Panel Initial Assessment of the National Cancer Plan: A Report to the President of the United States Remembering ...